These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 11828609)

  • 21. [Antihypertensive therapy in renal dysfunction].
    Ito S
    Nihon Rinsho; 2003 Jul; 61(7):1210-8. PubMed ID: 12877087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renoprotection and renin-angiotensin system blockade in diabetes mellitus.
    Ruilope LM
    Am J Hypertens; 1997 Dec; 10(12 Pt 2):325S-331S. PubMed ID: 9438777
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The protective effect of blocking angiotensin in both type I and type II diabetics with nephropathy.
    Beevers DG; Lip GY
    J Hum Hypertens; 2001 Dec; 15(12):837-9. PubMed ID: 11773985
    [No Abstract]   [Full Text] [Related]  

  • 24. A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension.
    Palmer AJ; Valentine WJ; Tucker DM; Ray JA; Roze S; Annemans L; Lapuerta P; Chen R; Gabriel S; Carita P; Rodby RA; de Zeeuw D; Parving HH; Laville M
    Curr Med Res Opin; 2006 Nov; 22(11):2095-100. PubMed ID: 17076969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers for diabetic nephropathy? A case for ACE inhibitors.
    Crook ED; Preddie DC
    Ethn Dis; 2002; 12(4):S3-49-52. PubMed ID: 12477155
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective.
    Coyle D; Rodby R; Soroka S; Levin A; Muirhead N; de Cotret PR; Chen R; Palmer A
    Clin Ther; 2007 Jul; 29(7):1508-23. PubMed ID: 17825702
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Can progression to terminal renal insufficiency be avoided in diabetic nephropathy?].
    Luño J; Valderrábano F
    An Med Interna; 1998 Nov; 15(11):567-71. PubMed ID: 9882851
    [No Abstract]   [Full Text] [Related]  

  • 28. Prevention of end-stage renal disease due to type 2 diabetes.
    Hostetter TH
    N Engl J Med; 2001 Sep; 345(12):910-2. PubMed ID: 11565525
    [No Abstract]   [Full Text] [Related]  

  • 29. [Hypertension and diabetic nephropathy, a dangerous duo].
    Hausberg M; Hohage H; Kosch M
    Med Klin (Munich); 2005 Nov; 100(11):729-37; quiz 738-9. PubMed ID: 16328181
    [No Abstract]   [Full Text] [Related]  

  • 30. Dual blockade of angiotensin II with enalapril and losartan reduces proteinuria in hypertensive patients with type 2 diabetes.
    Igarashi M; Hirata A; Kadomoto Y; Tominaga M
    Endocr J; 2006 Aug; 53(4):493-501. PubMed ID: 16829707
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiotensin-receptor blockers, type 2 diabetes, and renoprotection.
    Ceriello A; Motz E
    N Engl J Med; 2002 Feb; 346(9):705-7. PubMed ID: 11873779
    [No Abstract]   [Full Text] [Related]  

  • 32. Irbesartan prevents the progression of kidney disease or death in patients with type 2 diabetes and high blood pressure.
    Cardiovasc J S Afr; 2001; 12(4):240-1. PubMed ID: 11766617
    [No Abstract]   [Full Text] [Related]  

  • 33. [Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
    Parving HH; Lehnert H; Brøchner-Mortensen J; Gomis R; Andersen S; Arner P
    Ugeskr Laeger; 2001 Oct; 163(40):5519-24. PubMed ID: 11601118
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The kidney as a target organ in diabetic patients with arterial hypertension].
    Viberti G
    Drugs; 2003; 63 Spec No 1():31-7. PubMed ID: 12708880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EC approves irbesartan for the treatment of diabetic renal disease.
    Cardiovasc J S Afr; 2002; 13(4):216-7. PubMed ID: 12402931
    [No Abstract]   [Full Text] [Related]  

  • 36. [Angiotensin II receptor antagonists reduce the development of nephropathies in type 2 diabetes. Three new studies are of interest, but don't answer all questions].
    Nilsson P; Attvall S
    Lakartidningen; 2001 Nov; 98(45):4960-2. PubMed ID: 11816896
    [No Abstract]   [Full Text] [Related]  

  • 37. [Diabetic patient with hypertension takes A-I I blocker. Less likely dialysis].
    MMW Fortschr Med; 2002 Feb; 144(8):52. PubMed ID: 11910830
    [No Abstract]   [Full Text] [Related]  

  • 38. [Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy].
    Parving HH; Brenner BM; Cooper ME; de Zeeuw D; Keane WF; Mitch WE; Remuzzi G; Snapinn SM; Zhang Z; Shahinfar S
    Ugeskr Laeger; 2001 Oct; 163(40):5514-9. PubMed ID: 11601117
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings.
    Palmer AJ; Annemans L; Roze S; Lamotte M; Rodby RA; Cordonnier DJ
    Nephrol Dial Transplant; 2003 Oct; 18(10):2059-66. PubMed ID: 13679481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension].
    Palmer AJ; Annemans L; Roze S; Lamotte M; Rodby RA; Ritz E
    Dtsch Med Wochenschr; 2004 Jan; 129(1-2):13-8. PubMed ID: 14703575
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.